Assessing cost-effectiveness - Mental health: Introduction to the study and methods

Australian and New Zealand Journal of Psychiatry

Volumn 38, Issue 8, 2004, Pages 569-578

  Haby, Michelle M ^a   Carter, Rob ^b   Mihalopoulos, Cathrine ^b   Magnus, Anne ^a   Sanderson, Kristy ^c   Andrews, Gavin ^d   Vos, Theo ^a  

^a Public Health   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Anxiety disorders; Cost effectiveness; Depressive disorders; Health policy; Schizophrenia

Indexed keywords

CLOZAPINE; DEXAMPHETAMINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGORAPHOBIA; ARTICLE; ATTENTION DEFICIT DISORDER; AUSTRALIA; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; EVIDENCE BASED MEDICINE; GENERALIZED ANXIETY DISORDER; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; LONGITUDINAL STUDY; MAJOR DEPRESSION; MENTAL DISEASE; MENTAL HEALTH SERVICE; META ANALYSIS; MONTE CARLO METHOD; PANIC; PATIENT COMPLIANCE; RESOURCE ALLOCATION; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

ANXIETY DISORDERS; AUSTRALIA; COST-BENEFIT ANALYSIS; DECISION MAKING; DEPRESSIVE DISORDER, MAJOR; HEALTH POLICY; HUMANS; MENTAL HEALTH SERVICES; MONTE CARLO METHOD; SCHIZOPHRENIA;

EID: 4444258636     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1614.2004.01420.x     Document Type: Article

References (28)

1. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
2. Mathers C, Vos T, Stevenson C. The burden of disease and injury in Australia. Canberra: Australian Institute of Health and Welfare, 1999 (Available at: http://www.aihw,gov.au/publications/).
3. Vos T, Begg S. The Victorian Burden of Disease Study: morbidity. Melbourne: Public Health and Development Division, Department of Human Services, 1999.
4. Nathan PE, Gorman JM, eds. A guide to treatments that work. New York: Oxford University Press, 1998.
5. Andrews G, Sanderson K, Slade T, Issakidis C. Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment. Bulletin of the World Health Organization 2000; 78:446-454.
6. Carter R. The Macro Economic Evaluation Model (MEEM): an approach to priority setting in the health sector [PhD Thesis]. Melbourne: Monash University; 2001.
7. Carter R, Stone C, Vos T et al. Trial of program budgeting and marginal analysis (PBMA) to assist cancer control planning in Australia. Canberra: Commonwealth Department of Health and Aged Care, 2000.
8. Australian Bureau of Statistics. Mental health and wellbeing: profile of adults, Australia 1997. Canberra: Australian Bureau of Statistics, 1998.
9. Sawyer MG, Arney FM, Baghurst PA et al, The mental health of young people in Australia. Canberra: Mental Health and Special Programs Branch, Department of Health and Aged Care, 2000.
10. Jablensky A, McGrath J, Herrman H et al. People living with Psychotic illness: an Australian study 1997-1998. Canberra: Department of Health and Aged Care, 1999.
11. Stouthard MEA, Essink-Bot M, Bonsel GJ et al. Disability weights.for diseases in the Netherlands. Rotterdam: Department of Public Health, Erasmus University, 1997.
12. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG, eds. Systematic reviews in health care: meta-analysis in context, 2nd edn. London: BMJ Publishing Group, 2001; 285-312.
13. National Health and Medical Research Council. How to use the evidence: assessment and application of scientific evidence. Canberra: National Health and Medical Research Council, 2000.
14. Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. Clinical Psychology Review 1995; 15:819-844.
15. Rosenthal R. Meta-analytic procedures for social research. Newbury Park, CA: SAGE, 1991.
16. Egger M, Smith GD, Altman DG, eds. Systematic reviews in health care: meta-analysis in context, 2nd edn. London: BMJ Publishing Group, 2001.
17. The Quality Assurance Project. A treatment outline for depressive disorders. Australian and New Zealand Journal of Psychiatry 1983; 17:129-146.
18. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. New England Journal of Medicine 2001; 344:1594-1602.
19. Sanderson K, Andrews G, Corry J, Lapsley H. Using the effect size to model change in preference values from descriptive health states. Quality of Life Research 2004; 13:in press.
20. Ormel J, von Korff M, van den Brink W, Katon W, Oldehinkel T. Depression, anxiety, and social disability show synchrony of change in primary care patients. American Journal of Public Health 1993; 83:385-390.
21. Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology 1997; 17:298-307.
22. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, 2nd edn. Oxford: Oxford University Press, 1997.
23. Australian Institute of Health and Welfare. Health expenditure Australia 2000-01. Health and Welfare Expenditure Series no. 14. Canberra: Australian Institute of Health and Welfare, 2002.
24. Palisade Corporation. RISK [computer program] Risk Analysis Add-in for Microsoft Excel, Version 4. Newfield, NY: Palisade Corporation, 2001.
25. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada, 2nd edn. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997.
26. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine 2002; 21:1575-1600.
27. Gureje O, Herrman H, Harvey C, Trauer T, Jablensky A. Defining disability in psychosis. Performance of the diagnostic interview for psychosis-disability module (DIP-DIS) in the Australian National Survey of Psychotic Disorders. Australian and New Zealand Journal (Psychiatry 2001; 35:846-851.
28. Richardson J, Olsen J, Hawthorne G, Mortimer D, Smith R. The measurement and valuation utility based quality of life: Recommendations from a review of the literature. CHPE Working Paper. Melbourne: Centre for Health Program Evaluation, 1999.